Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
Ingredion's takeover bid for Tate & Lyle

Ingredion's takeover bid for Tate & Lyle

Money Moves

U.S. ingredients maker proposes £2.74B all-cash deal for its London-listed rival

2 days ago: Ingredion's £2.74B proposal becomes public

Overview

American ingredients maker Ingredion has proposed buying its British rival Tate & Lyle for £2.74 billion in cash. The 595-pence-per-share offer is 64% above where Tate & Lyle traded before the talks surfaced.

A combined company would supply much of the world's corn-derived sweeteners, texturants and specialty fibres used in soft drinks, baked goods and plant-based meat. Tate & Lyle would also join the growing list of UK-listed firms moving into U.S. ownership. Ingredion has until June 11 to make a firm offer under UK takeover rules, or walk away for six months.

Why it matters

If completed, the deal removes another large company from the London Stock Exchange and consolidates global food ingredient supply into fewer hands.

Play on this story Voices Debate Predict

Key Indicators

£2.74B
Proposed deal value
All-cash offer for Tate & Lyle, equivalent to about $3.7 billion.
64%
Premium over prior close
Implied premium over the 374.80p closing price before talks surfaced.
615p
Maximum per-share consideration
595p cash plus up to 20p in dividends Tate & Lyle shareholders can keep.
June 11
Put Up or Shut Up deadline
UK Takeover Code date by which Ingredion must announce a firm offer or step back.

Interactive

Exploring all sides of a story is often best achieved with Play.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

Nick Hampton
Nick Hampton
Leading discussions with advisers on Ingredion's proposal
 James P. Zallie
James P. Zallie
Has until June 11 to make a firm offer

Organizations Involved

Tate & Lyle PLC
Tate & Lyle PLC
Public company (LSE: TATE)
Target of Ingredion proposal; in discussions with advisers

British food and beverage ingredients company specialising in sweeteners, texturants and dietary fibres.
Ingredion Inc.
Ingredion Inc.
Public company (NYSE: INGR)
Bidder; faces June 11 PUSU deadline

Chicago-based maker of food and industrial ingredients derived from corn, tapioca, potato and other plant sources.

Timeline

  1. Ingredion's £2.74B proposal becomes public

    M&A Proposal

    Ingredion proposes acquiring Tate & Lyle at 595 pence per share in cash, valuing the company at about £2.74 billion. Tate & Lyle confirms it is in discussions with advisers. The 28-day Put Up or Shut Up clock starts under the UK Takeover Code.

  2. CP Kelco acquisition completes

    M&A

    Tate & Lyle closes the CP Kelco deal, becoming a pure-play specialty food ingredients group with combined revenue above $3.4 billion.

  3. Tate & Lyle agrees CP Kelco deal

    M&A

    Tate & Lyle agrees to buy specialty texturants and biopolymer maker CP Kelco from J.M. Huber for $1.8 billion. The acquisition is its largest in years and its central bet on specialty ingredients.

  4. Tate & Lyle completes Primient joint venture

    Corporate Action

    Tate & Lyle sells a controlling stake in its U.S. corn-syrup and bulk-sweeteners business into a joint venture with KPS Capital Partners, branded Primient, for $1.7 billion. The deal completes its exit from commodity sweeteners.

  5. Nick Hampton becomes Tate & Lyle CEO

    Leadership

    Hampton takes over from Javed Ahmed after three years as Chief Financial Officer. He signals plans to accelerate the company's shift toward specialty food ingredients.

  6. James Zallie takes over at Ingredion

    Leadership

    Zallie becomes CEO of Ingredion after running its specialty ingredients arm. He pushes the company harder toward higher-margin specialty products and away from commodity sweeteners.

  7. Tate & Lyle exits European sugar refining

    Corporate Action

    Tate & Lyle completes sale of its European sugar refining operations, including the Thames Refinery, to American Sugar Refining for £211 million. It is the company's first major step away from its founding commodity business.

Scenarios

Predict which scenario wins. Contrarian picks score more — points lock in when the scenario resolves.

Log in to predict. Track your picks, climb the leaderboard. Log in Sign Up
1

Ingredion files firm offer before PUSU deadline

Tate & Lyle's board is already in talks with advisers. The 64% premium signals Ingredion is willing to negotiate, and most public possible-offer announcements at this stage progress to a firm Rule 2.7 offer. A modest price bump to win a board recommendation is the most likely path through the June 11 deadline.

Resolves by: 2026-06-11
Source: Tate & Lyle Regulatory News Service (RNS) announcement / UK Takeover Panel
Discussed by: Tate & Lyle board statement; standard UK Takeover Code base case
Consensus —
2

Ingredion walks away at PUSU deadline

If Tate & Lyle's board demands a price Ingredion considers too high, or due diligence surfaces problems, Ingredion can withdraw before June 11. The Code would then bar a new approach for six months. This outcome is unusual after a public 64% premium has been put on the table, but it is the clean exit if talks break down.

Resolves by: 2026-06-11
Source: Ingredion or Tate & Lyle RNS / press release
Discussed by: Standard UK Takeover Code exit route
Consensus —
3

Counter-bidder emerges before deal closes

A few large agribusiness and chemicals groups, including Archer-Daniels-Midland, Cargill and BASF, could in theory match or outbid Ingredion. Antitrust concerns make a strategic counter-bid difficult, particularly for ADM. A private equity interloper is possible but would need to justify a premium above 615p without the cost synergies a strategic acquirer can claim.

Resolves by: 2026-12-31
Source: Tate & Lyle RNS announcements
Discussed by: Sector consolidation watchers
Consensus —
4

Acquisition completes, Tate & Lyle delisted

A firm offer at this size triggers shareholder votes plus UK Competition and Markets Authority review and likely also U.S. and EU antitrust scrutiny. Deals of this scale routinely take 9 to 15 months to close after a firm offer. Completion before mid-2027 requires a clean regulatory path and no major rival emerging.

Resolves by: 2027-06-30
Source: London Stock Exchange delisting notice / Tate & Lyle RNS
Discussed by: Standard cross-border M&A timetable
Consensus —

Historical Context

Kraft-Cadbury takeover (2010)

September 2009 – February 2010

What Happened

Kraft Foods launched a £10.2 billion hostile bid for Cadbury in September 2009. After raising the offer to £11.5 billion and winning over Cadbury's largest shareholders, the deal closed in February 2010. Kraft then closed a Cadbury factory in Somerdale it had pledged to keep open, triggering political backlash.

Outcome

Short Term

Cadbury was delisted from London and folded into Kraft's confectionery business. Kraft later spun the unit out as Mondelez International in 2012.

Long Term

The UK Takeover Panel tightened the Code in 2011, introducing the 28-day Put Up or Shut Up deadline and requiring bidders to disclose financing details. Those rules now apply to Ingredion.

Why It's Relevant Today

Sets the rulebook Ingredion is operating under. Also a reminder that US bids for British food companies can complete despite political resistance, particularly when the premium is large.

Pfizer's bid for AstraZeneca (2014)

April – May 2014

What Happened

U.S. drugmaker Pfizer made a £69 billion approach for AstraZeneca in April 2014, partly driven by tax inversion. AstraZeneca's board rejected the offer as undervaluing the company. Pfizer walked away in late May after UK political opposition and shareholder pushback.

Outcome

Short Term

AstraZeneca remained independent. Its shares fell back below Pfizer's offer level in the months after the bid lapsed.

Long Term

AstraZeneca's standalone strategy paid off. Its market value by 2024 far exceeded Pfizer's 2014 offer. The U.S. Treasury later tightened tax inversion rules.

Why It's Relevant Today

Shows that a determined target board can defeat even a generous US bid, particularly when the deal becomes politically sensitive. Tate & Lyle does not have AstraZeneca's UK political profile, but its board has the same option to demand more.

Kraft Heinz's approach for Unilever (2017)

February 2017

What Happened

Kraft Heinz, backed by 3G Capital and Berkshire Hathaway, made a $143 billion approach for Unilever in February 2017. Unilever's board rejected it as inadequate within 48 hours. Kraft Heinz withdrew the offer two days later.

Outcome

Short Term

Unilever launched a strategic review, accelerated cost cuts and bought back £5 billion of shares. It later sold its margarine business to KKR.

Long Term

Unilever stayed independent and unified its corporate structure into a single UK-listed entity in 2020. Kraft Heinz wrote down $15 billion of brand value in 2019.

Why It's Relevant Today

Shows how fast a public approach can collapse if the target board moves decisively. Also shows that resisting a takeover can pay off for shareholders long-term.

Sources

(3)
Bloomberg Tate & Lyle PLC Crain's Chicago Business